The Effect of Alkyl Substituents on the Formation and Structure of Homochiral (*,*)-[RGa(-OCH(Me)COR')] Species-Towards the Factors Controlling the Stereoselectivity of Dialkylgallium Alkoxides in the Ring-Opening Polymerization of -Lactide.

Building on our previous studies, which have demonstrated that homochiral propagating species-(*,*)-[MeGa(-OCH(Me)COR)]-were crucial for the heteroselectivity of [MeGa(-OCH(Me)COMe)] in the ring-opening polymerization (ROP) of racemic lactide (-LA), we have investigated the effect of alkyl groups on the structure and catalytic properties of dialkylgallium alkoxides in the ROP of -LA. Therefore, we have isolated and characterized the -[RGa(-OCH(Me)COMe] (R = Et (), Pr () and -[RGa(-OCH(Me)CHN] (R = Et (), Pr ()) complexes, to demonstrate the effect of alkyl groups on the chiral recognition induced the formation of the respective homochiaral species-(*,*)-[RGa(-OCH(Me)COMe)] and (*,*)-[RGa(-OCH(Me)CHN]. Moreover, we have investigated the structure of (,)-[RGa(-OCH(Me)COMe] (R = Et ((,)-, R = Pr ((,)-,) and their catalytic activity in the ROP of -LA.

-Difluorovinyl and trifluorovinyl Michael acceptors in the synthesis of α,β-unsaturated fluorinated and nonfluorinated amides.

The incorporation of fluorine atoms within the structure of organic compounds is known to exert a significant impact on their electronic properties, thereby modulating their reactivity in diverse chemical transformations. In the context of our investigation, we observed a striking illustration of this phenomenon. A Michael addition involving -difluorovinyl and trifluorovinyl acceptors was successfully achieved, demonstrating high stereoselectivity.

Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension.

Primary immune thrombocytopenia (ITP) is an antiplatelet-antibody-mediated disorder with accelerated platelet clearance and decreased platelet production. Rozanolixizumab, a monoclonal IgG4 anti-FcRn antibody, blocks IgG recycling and decreases IgG levels. We report efficacy and safety of rozanolixizumab in adults with persistent/chronic ITP in 24-week phase 3 studies (TP0003; TP0006), and their 52-week open-label extension (OLE).